Danaher (DHR) – PRNewswire
-
Danaher Reports First Quarter 2024 Results
-
Cepheid Announces World Health Organization Prequalification of Xpert HIV-1 Qualitative Test
-
Danaher Schedules First Quarter 2024 Earnings Conference Call
-
Cepheid Receives FDA Clearance for Xpert® Xpress GBS
-
Danaher to Present at TD Cowen Health Care Conference
-
Danaher Commits to Set Science-Based, Net-Zero Greenhouse Gas Emission Reduction Targets
-
Danaher Announces Quarterly Dividend
-
Danaher Launches Collaboration with Cincinnati Children's Hospital Medical Center Aiming to Improve Patient Safety in Early Drug Development
-
Danaher Reports Fourth Quarter and Full Year 2023 Results
-
Cepheid Receives Expanded FDA Clearance with CLIA Waiver for Xpert® Xpress MVP
-
Danaher, Jennifer Doudna, and Innovative Genomics Institute Launch Danaher-IGI Beacon for CRISPR Cures with Aim to Address Hundreds of Diseases Using Gene-editing Platform Solution
-
Danaher CEO to Comment on Financial Performance
-
Danaher to Present at J.P. Morgan Healthcare Conference
-
Danaher Schedules Fourth Quarter 2023 Earnings Conference Call
-
Danaher Completes Acquisition of Abcam
-
Danaher Announces Quarterly Dividend
-
Danaher to Present at Evercore ISI HealthCONx Conference
-
Danaher appoints Christopher Riley to Executive Vice President for Biotechnology
-
Danaher Reports Third Quarter 2023 Results
-
Danaher Corporation Completes Separation of Veralto Corporation
-
Veralto Set to Join S&P 500; Vestis to Join S&P MidCap 400; Others to Join S&P SmallCap 600
-
Danaher Schedules Third Quarter 2023 Earnings Conference Call
-
Danaher to Provide Cepheid's Tuberculosis Test to the Global Fund at Cost
-
Danaher Announces Quarterly Dividend
-
Danaher and Veralto to Webcast Investor and Analyst Meeting
-
Danaher to Acquire Abcam
-
Danaher Declares pro Rata Dividend of Veralto Common Stock and Announces Expected "When-issued" Trading of Veralto Common Stock
-
Danaher Releases 2023 Sustainability Report
-
Beckman Coulter's DxI 9000 Immunoassay Analyzer with Increased Assay Development Sensitivity Makes First North American Appearance at 2023 AACC
-
Beckman Coulter Receives FDA Clearance for DxC 500 AU Chemistry Analyzer, Expanding Portfolio with Proven Six Sigma Performance
-
Danaher Reports Second Quarter 2023 Results
-
Beckman Coulter Connects Scopio Labs Digital Cell Morphology with Hematology Workcell Extending Automated Workflow
-
Beckman Coulter and Fujirebio Partner to Bolster Access to Patient-friendly, Blood-based Alzheimer's Disease Test
-
Danaher Schedules Second Quarter 2023 Earnings Conference Call
-
Beckman Coulter Unveils Next Generation Immunoassay Analyzer Enabling Elite Laboratory Performance with No Daily Maintenance
-
Danaher Announces Quarterly Dividend
-
Danaher to Present at Bank of America Securities Health Care Conference
-
ALDEVRON ANNOUNCES EXPANSION OF mRNA PRODUCTION CAPABILITY
-
Danaher Reports First Quarter 2023 Results
-
Danaher Announces Conversion Date for Series B Mandatory Convertible Preferred Stock
-
Danaher Schedules First Quarter 2023 Earnings Conference Call
-
Danaher Partners with the University of Pennsylvania's Center for Cellular Immunotherapies to Address Manufacturing Challenges Impacting the Uptake of Cell Therapies
-
Danaher Announces Quarterly Dividends
-
Danaher Announces New Environmental and Applied Solutions Company to Be Named Veralto
-
Beckman Coulter and MeMed to Expand Access to Proven Host Immune Response Diagnostic Able to Distinguish Between Bacterial and Viral Infections
-
Danaher Reports Fourth Quarter and Full Year 2022 Results
-
Danaher CEO to Comment on Financial Performance
-
Danaher to Present at J.P. Morgan Healthcare Conference
-
Danaher Schedules Fourth Quarter 2022 Earnings Conference Call
-
Danaher Announces Quarterly Dividends
Back to DHR Stock Lookup
